AstraZeneca forecast Covid-19 medicine sales to decline "significantly" in 2023, with "minimal revenue" from its jab Vaxzevria. "2022 was a year of continued strong company performance and execution of our long-term growth strategy," group chief executive Pascal Soriot said in the statement. "In 2023, we expect to see another year of double-digit revenue growth, excluding our Covid-19 medicines." The group forecast that total revenues would climb between one and five percent this year.